Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parsaclisib - Incyte Corporation

X
Drug Profile

Parsaclisib - Incyte Corporation

Alternative Names: IBI-376; INCB-050465; INCB-50465

Latest Information Update: 15 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Incyte Corporation; Innovent Biologics; Mayo Clinic; National Cancer Institute (USA)
  • Class Antianaemics; Antihaemorrhagics; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Ketones; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Marginal zone B-cell lymphoma; Autoimmune haemolytic anaemia; Mantle-cell lymphoma; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Follicular lymphoma
  • Phase III Myelofibrosis
  • Phase II B-cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
  • Phase I/II Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Solid tumours
  • Preclinical Systemic lupus erythematosus
  • Discontinued Autoimmune haemolytic anaemia; Sjogren's syndrome

Most Recent Events

  • 02 Apr 2024 Incyte Corporation completes a phase II trial in Autoimmune haemolytic anaemia (Treatment experienced)in the US, Austria, France and Italy (PO) (NCT03538041)
  • 09 Dec 2023 Efficacy and safety data from a phase I/II trial in Peripheral T-cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 17 Oct 2023 Innovent Biologics withdraws a phase I trial in Follicular Lymphoma prior to enrolment (NCT05867030)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top